| Literature DB >> 25755824 |
Qian Yang1, Xuanxuan Zhou1, Meng Zhang1, Linlin Bi1, Shan Miao1, Wei Cao1, Yanhua Xie1, Jiyuan Sun1, Haifeng Tang1, Ying Li1, Qing Miao1, Siwang Wang1.
Abstract
There are currently 34 genera and 410 species of toads in the world. The medicinal parts of toads mainly include their venom, skin, and clothing. The toad's venom and skin possess the same chemical components, mainly the toad venom lactone class, and their pharmacological effects primarily include the maintenance of strong heart, antitumor, antivirus, anti-infection, and analgesic effects. So far, the produces from the medicinal raw materials of the toad are widely used clinically around the world, especially in China, Japan, and South Korea. About 50 varieties of medicines are used in the clinical treatment of various complicated diseases in China, such as "Liushen pills" which was popular in the whole world. Toads are mainly used in treating malignant tumors (e.g., liver cancer, gastric cancer, esophageal cancer, colon cancer, cervical cancer, among others), and some major diseases such as hepatitis B. Despite the therapeutic effects of toad-derived medicines on human health, there is insufficient research and development of toad-derived medicines by leading drug companies. In order to harness the beneficial effects of the resources of the toad species, it is the responsibility of global pharmaceutical researchers to develop and generate economically feasible toad-derived therapeutic products, while promoting maximum protection to the resources of the toad species.Entities:
Keywords: Toad; cancer; hepatitis B
Year: 2015 PMID: 25755824 PMCID: PMC4346519
Source DB: PubMed Journal: Am J Transl Res Impact factor: 4.060